Given the well-known drug–drug interactions due to being a substrate for CYP2C19, CYP2C9 and CYP3A4, voriconazole interacts with COVID-19 therapy, such as remdesivir, which is also metabolized via CYP3A4 [4]. The gene discussed is CYP3A4; the disease is COVID-19.